Effects of phencyclidine on spatial learning and memory: Nitric oxide-dependent mechanisms

Behavioural Brain Research

Volumn 171, Issue 1, 2006, Pages 147-153

  Wass, Caroline ^a   Archer, Trevor ^b   Pålsson, Erik ^a   Fejgin, Kim ^a   Klamer, Daniel ^a   Engel, Jörgen A ^a   Svensson, Lennart ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

l NAME; Morris water maze; Nitric oxide; Phencyclidine

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG EFFECT; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HALLUCINOGENS; MALE; MAZE LEARNING; MEMORY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RETENTION (PSYCHOLOGY); SPACE PERCEPTION;

EID: 33646564366     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.03.036     Document Type: Article

References (52)

1. Ahlander M., Misane I., Schott P.A., and Ogren S.O. A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 21 (1999) 414-426
2. Baldi E., Efoudebe M., Lorenzini C.A., and Bucherelli C. Spatial navigation in the Morris water maze: working and long lasting reference memories. Neurosci Lett 378 (2005) 176-180
3. Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia: a review. Schizophr Res 2005.
4. Bouger P.C., and van der Staay F.J. Rats with scopolamine- or MK-801-induced spatial discrimination deficits in the cone field task: animal models for impaired spatial orientation performance. Eur Neuropsychopharmacol 15 (2005) 331-346
5. Butcher S.P., Davis S., and Morris R.G. A dose-related impairment of spatial learning by the NMDA receptor antagonist 2-amino-5-phosphonovalerate (AP5). Eur Neuropsychopharmacol 1 (1990) 15-20
6. Carlson N.R. Relational learning and amnesia. In: Wakely S.W. (Ed). Physiology of behavior (1998), Allyn and Bacon, Needham Heights, MA 452-476
7. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl (1999) 2-6
8. Carlsson M., and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13 (1990) 272-276
9. Carter C., Robertson L., Nordahl T., Chaderjian M., Kraft L., and O'Shora-Celaya L. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry 40 (1996) 930-932
10. Chapman P.F., Atkins C.M., Allen M.T., Haley J.E., and Steinmetz J.E. Inhibition of nitric oxide synthesis impairs two different forms of learning. Neuroreport 3 (1992) 567-570
11. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., and Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 56 (2004) 129-134
12. Cirillo M.A., and Seidman L.J. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev 13 (2003) 43-77
13. Cosway R., Byrne M., Clafferty R., Hodges A., Grant E., Abukmeil S.S., et al. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med 30 (2000) 1111-1121
14. Deutsch S.I., Rosse R.B., Schwartz B.L., Fay-McCarthy M., Rosenberg P.B., and Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 20 (1997) 357-363
15. Fejgin K., Pålsson E., Wass C., Engel J.A., Svensson L., and Klamer D. Local injection of the soluble guanylyl cyclase inhibitor ODQ into the mouse medial prefrontal cortex blocks phencyclidine-induced disruption of prepulse inhibition (2005), Society for Neuroscience, Washington, DC, USA
16. Gold J.M., Carpenter C., Randolph C., Goldberg T.E., and Weinberger D.R. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54 (1997) 159-165
17. Goldman-Rakic P.S. Cellular and circuit basis of working memory in prefrontal cortex of nonhuman primates. Prog Brain Res 85 (1990) 325-335 [discussion 335-326]
18. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
19. Green M.F., and Braff D.L. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49 (2001) 374-384
20. Hoehn-Saric R., McLeod D.R., and Glowa J.R. The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response. Biol Psychiatry 30 (1991) 170-176
21. Hoiseth G., Hjelmeland K., and Bachs L. Phencyclidine-angel dust. Tidsskr Nor Laegeforen 125 (2005) 2775-2776
22. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
23. Johansson C., Jackson D.M., and Svensson L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl) 131 (1997) 167-173
24. Kapur S., and Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7 (2002) 837-844
25. Karatinos J., Rosse R.B., and Deutsch S.I. The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 18 (1995) 482-499
26. Karolewicz B., Szebeni K., Stockmeier C.A., Konick L., Overholser J.C., Jurjus G., et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 91 (2004) 1057-1066
27. Kesslak J.P., Chuang K.R., and Berchtold N.C. Spatial learning is delayed and brain-derived neurotrophic factor mRNA expression inhibited by administration of MK-801 in rats. Neurosci Lett 353 (2003) 95-98
28. Klamer D., Engel J.A., and Svensson L. The nitric oxide synthase inhibitor, l-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 156 (2001) 182-186
29. Klamer D., Engel J.A., and Svensson L. Phencyclidine-induced behaviour in mice prevented by methylene blue. Pharmacol Toxicol 94 (2004) 65-72
30. Klamer D, Palsson E, Fejgin K, Zhang J, Engel JA, Svensson L. Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition. Psychopharmacology (Berl) 2004.
31. Klamer D., Palsson E., Revesz A., Engel J.A., and Svensson L. Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 176 (2004) 440-450
32. Klamer D., Palsson E., Wass C., Archer T., Engel J.A., and Svensson L. Antagonism of the nitric oxide synthase inhibitor, l-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning. Behav Brain Res 161 (2005) 60-68
33. Klamer D., Zhang J., Engel J.A., and Svensson L. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav Brain Res 159 (2005) 95-103
34. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
35. Lee I., and Kesner R.P. Differential contribution of NMDA receptors in hippocampal subregions to spatial working memory. Nat Neurosci 5 (2002) 162-168
36. Lu Y.F., Kandel E.R., and Hawkins R.D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19 (1999) 10250-10261
37. Majlessi N., Kadkhodaee M., Parviz M., and Naghdi N. Serotonin depletion in rat hippocampus attenuates l-NAME-induced spatial learning deficits. Brain Res 963 (2003) 244-251
38. McGurk S.R. Neurocognition as a determinant of employment status in schizophrenia. J Psychiatr Pract 6 (2000) 190-196
39. McGurk S.R., Green M.F., Wirshing W.C., Wirshing D.A., Marder S.R., Mintz J., et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 68 (2004) 225-233
40. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 11 (1984) 47-60
41. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr Res 72 (2004) 29-39
42. O'Dell T.J., Hawkins R.D., Kandel E.R., and Arancio O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci USA 88 (1991) 11285-11289
43. Okuyama S., Ogawa S., Nakazato A., and Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 189 (1995) 60-62
44. Palsson E., Klamer D., Wass C., Archer T., Engel J.A., and Svensson L. The effects of phencyclidine on latent inhibition in taste aversion conditioning: differential effects of preexposure and conditioning. Behav Brain Res 157 (2005) 139-146
45. Podhorna J., and Didriksen M. Performance of male C57BL/6J mice and Wistar rats in the water maze following various schedules of phencyclidine treatment. Behav Pharmacol 16 (2005) 25-34
46. Ramirez J., Garnica R., Boll M.C., Montes S., and Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res 68 (2004) 357-361
47. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 2006.
48. Rushe T.M., Woodruff P.W., Murray R.M., and Morris R.G. Episodic memory and learning in patients with chronic schizophrenia. Schizophr Res 35 (1999) 85-96
49. Thermenos H.W., Goldstein J.M., Buka S.L., Poldrack R.A., Koch J.K., Tsuang M.T., et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res 74 (2005) 179-194
50. Varvel S.A., Hamm R.J., Martin B.R., and Lichtman A.H. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology 157 (2001) 142-150
51. Wesierska M., Macias-Gonzalez R., and Bures J. Differential effect of ketamine on the reference and working memory versions of the Morris water maze task. Behav Neurosci 104 (1990) 74-83
52. Zou L.B., Yamada K., Tanaka T., Kameyama T., and Nabeshima T. Nitric oxide synthase inhibitors impair reference memory formation in a radial arm maze task in rats. Neuropharmacology 37 (1998) 323-330